Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study

被引:3
|
作者
Fatima, Shehnaz [1 ]
Agarwal, Subhash Mohan [1 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, 1-7,Sect 39, Noida 201301, India
关键词
EGFR; double mutant inhibitor; QSAR; TMLR; CELL LUNG-CANCER; DRUG-RESISTANCE; MODEL; MUTATION; DESIGN;
D O I
10.1080/10799893.2018.1494740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EGFR is an important drug target in cancer. However, the ineffectiveness of first generation inhibitors due to the occurrence of a secondary mutation (T790M) results in the relapse of the disease. Identification of reversible inhibitors against T790M/L858R double mutants (TMLR) thus is a foremost requirement. In this study, various 2 D and 3 D Quantitative Structure-Activity Relationship models were built for amino-pyrimidine compounds with their known biological activity against TMLR mutants. The model developed using multiple linear regression statistical method via stepwise forward-backward variable selection technique showed the best results in terms of internal and external predictivity. The 2D-QSAR model indicated that the presence of electronegative atom, H-bond donors, moderate slogp, count of number of N atoms separated from O (T_N_O_4), 4pathClusterCount and number of S atom connected with two single bonds (SssSE-index), is required for increasing the inhibitory potential of compounds. Also, the 3D-QSAR model suggested that electronegative group at certain positions along with the presence of bulky groups is beneficial for good inhibition activity of the compounds. Thus, the QSAR models developed in the present work can be used for predicting the TMLR bioactivity of a new series of amino-pyrimidine derivatives. To the best of the author's knowledge, this is the first study which deals with the development of 2 D and 3D-QSAR models for double mutant TMLR inhibitors.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 50 条
  • [21] Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
    Wu, Hong
    Wang, Aoli
    Zhang, Wei
    Wang, Beilei
    Chen, Cheng
    Wang, Wenchao
    Hu, Chen
    Ye, Zi
    Zhao, Zheng
    Wang, Li
    Li, Xixiang
    Yu, Kailin
    Liu, Juan
    Wu, Jiaxin
    Yan, Xiao-E
    Zhao, Peng
    Wang, Jinhua
    Wang, Chu
    Weisberg, Ellen L.
    Gray, Nathanael S.
    Yun, Cai-Hong
    Liu, Jing
    Chen, Liang
    Liu, Qingsong
    ONCOTARGET, 2015, 6 (31) : 31313 - 31322
  • [22] Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach
    Agarwal, Subhash M.
    Nandekar, Prajwal
    Saini, Ravi
    RSC ADVANCES, 2022, 12 (26) : 16779 - 16789
  • [23] Identification of Novel Fourth-Generation Allosteric Inhibitors Targeting Inactive State of EGFR T790M/L858R/C797S and T790M/L858R Mutations: A Combined Machine Learning and Molecular Dynamics Approach
    Bhanja, Kousik K.
    Patra, Niladri
    JOURNAL OF PHYSICAL CHEMISTRY B, 2025,
  • [24] Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC
    Chen, Lingfeng
    Fu, Weitao
    Feng, Chen
    Qu, Rong
    Tong, Linjiang
    Zheng, Lulu
    Fang, Bo
    Qiu, Yinda
    Hu, Jie
    Cai, Yuepiao
    Feng, Jianpeng
    Xie, Hua
    Ding, Jian
    Liu, Zhiguo
    Liang, Guang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 140 : 510 - 527
  • [25] Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
    Juchum, Michael
    Guenther, Marcel
    Doering, Eva
    Sievers-Engler, Adrian
    Laemmerhofer, Michael
    Laufer, Stefan
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (11) : 4636 - 4656
  • [26] Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant
    Fukuda, Tsutomu
    Anzai, Mizuho
    Nakahara, Akane
    Yamashita, Kentaro
    Matsukura, Kazuaki
    Ishibashi, Fumito
    Oku, Yusuke
    Nishiya, Naoyuki
    Uehara, Yoshimasa
    Iwao, Masatomo
    BIOORGANIC & MEDICINAL CHEMISTRY, 2021, 34
  • [27] Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC
    Chen, Lixue
    Zhang, Yunhao
    Tian, Liangliang
    Wang, Changyuan
    Deng, Tuo
    Zheng, Xu
    Wang, Tong
    Li, Zhen
    Tang, Zeyao
    Meng, Qiang
    Sun, Huijun
    Li, Lei
    Ma, Xiaodong
    Xu, Youjun
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 223
  • [28] Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant
    Qin, Xuemei
    Li, Zhipeng
    Yang, Leifu
    Liu, Peng
    Hu, Liming
    Zeng, Chengchu
    Pan, Zhiyong
    BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 24 (13) : 2871 - 2881
  • [29] Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor
    Yang, Zichao
    Yang, Haikui
    Ai, Yangcheng
    Zhang, Lishun
    Li, Zhonghuang
    Wan, Shanhe
    Xu, Xuan
    Zhang, Huiwu
    Wu, Shaoyu
    Zhang, Jiajie
    Zhang, Tingting
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 152
  • [30] Lung Cancer: EGFR Inhibitors with Low Nanomolar Activity against a Therapy-Resistant L858R/T790M/C797S Mutant
    Guenther, Marcel
    Juchum, Michael
    Kelter, Gerhard
    Fiebig, Heiner
    Laufer, Stefan
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (36) : 10890 - 10894